The purpose of this study is to evaluate the effect of ALN-AGT01 on systolic and
diastolic blood pressure and to characterize the pharmacodynamic (PD) effects and safety
of ALN-AGT01.

A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension

Hypertension

Participants will receive ALN-AGT01 or placebo for the first 6 months of the 12-month
double-blind (DB) treatment period. Participants randomized to placebo will be
re-randomized at Month 6 to 1 of the 4 initial ALN-AGT01 regimens until the end of the
12-month DB treatment period. Participants randomized to ALN-AGT01 regimens will remain
on their originally assigned regimens through remainder of the study.

Zilebesiran

Clinical Trial Site

A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension

Multiple doses of ALN-AGT01 administered by subcutaneous (SC) injection during the
12-month DB treatment period.

Multiple doses of ALN-AGT01 administered by SC injection during the 12-month DB treatment
period.

Multiple doses of placebo administered by SC injection during the first 6 months of
12-month DB treatment period, followed by multiple doses of ALN-AGT01 administered by SC
injection during the last 6 months of the 12-month DB treatment period.